Fatih Demırkan
- Genetics top 2%
- Pathology and Forensic Medicine top 2%
- Hematology top 5%
- Immunology top 10%
- Oncology
- Co-authors
- Mehmet Ali ÖzcanCarol MorenoBülent ÜndarAlessandra TedeschiMartin ŠimkovičJohn G. GribbenRichard GreilDevinder Gill
- Topics
- Chronic Lymphocytic Leukemia Research (26 papers)Lymphoma Diagnosis and Treatment (22 papers)Chronic Myeloid Leukemia Treatments (14 papers)
- Journals
- Journal of Clinical OncologySHILAP Revista de lepidopterologíaBlood
- Partner nations
- TürkiyeUnited StatesSpain
In The Last Decade
Fatih Demırkan
71 papers receiving 909 citations
Hit Papers
Peers
Comparison fields: 5 of 72
- Genetics 581
- Pathology and Forensic Medicine 489
- Hematology 302
- Immunology 220
- Oncology 179
Countries citing papers authored by Fatih Demırkan
This map shows the geographic impact of Fatih Demırkan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fatih Demırkan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fatih Demırkan more than expected).
Fields of papers citing papers by Fatih Demırkan
This network shows the impact of papers produced by Fatih Demırkan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fatih Demırkan. The network helps show where Fatih Demırkan may publish in the future.
Co-authorship network of co-authors of Fatih Demırkan
This figure shows the co-authorship network connecting the top 25 collaborators of Fatih Demırkan. A scholar is included among the top collaborators of Fatih Demırkan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fatih Demırkan. Fatih Demırkan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 3 | |
| 3 | 0 | |
| 4 | 1 | |
| 5 | 9 | |
| 6 | 8 | |
| 7 | Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trialbreakdown → | 380 |
| 8 | 3 | |
| 9 | 2 | |
| 10 | IBRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): 2-YEAR FOLLOW-UP INCLUDING MRD FROM THE HELIOS STUDY | 4 |
| 11 | 1 | |
| 12 | 5 | |
| 13 | 10 | |
| 14 | 3 | |
| 15 | 5 | |
| 16 | 4 | |
| 17 | 19 | |
| 18 | 1 | |
| 19 | 12 | |
| 20 | 14 |
About Fatih Demırkan
Fatih Demırkan is a scholar working on Hematology, Genetics and Pathology and Forensic Medicine, having authored 82 papers that have together received 926 indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (26 papers), Lymphoma Diagnosis and Treatment (22 papers) and Chronic Myeloid Leukemia Treatments (14 papers). The work is most often cited by research in Genetics (581 citations), Pathology and Forensic Medicine (489 citations) and Hematology (302 citations). Fatih Demırkan has collaborated with scholars based in Türkiye, United States and Spain. Frequent co-authors include Mehmet Ali Özcan, Carol Moreno, Bülent Ündar, Alessandra Tedeschi, Martin Šimkovič, John G. Gribben, Richard Greil, Devinder Gill, Bertrand Anz and Emily Hsu. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.